234 related articles for article (PubMed ID: 17517836)
1. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Hecht DW; Galang MA; Sambol SP; Osmolski JR; Johnson S; Gerding DN
Antimicrob Agents Chemother; 2007 Aug; 51(8):2716-9. PubMed ID: 17517836
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Karlowsky JA; Laing NM; Zhanel GG
Antimicrob Agents Chemother; 2008 Nov; 52(11):4163-5. PubMed ID: 18725442
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
Huhulescu S; Sagel U; Fiedler A; Pecavar V; Blaschitz M; Wewalka G; Allerberger F; Indra A
J Med Microbiol; 2011 Aug; 60(Pt 8):1206-1212. PubMed ID: 21292853
[TBL] [Abstract][Full Text] [Related]
5. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
O'Connor JR; Galang MA; Sambol SP; Hecht DW; Vedantam G; Gerding DN; Johnson S
Antimicrob Agents Chemother; 2008 Aug; 52(8):2813-7. PubMed ID: 18559647
[TBL] [Abstract][Full Text] [Related]
6. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Liao CH; Ko WC; Lu JJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Jul; 56(7):3943-9. PubMed ID: 22508299
[TBL] [Abstract][Full Text] [Related]
7. [In Vitro Activities of Antimicrobials Against Toxigenic Clostridioides difficile Isolates Obtained in a University Training and Research Hospital in Turkey].
Sayın E; Bilgin H; Söyletir G; Ülger Toprak N
Mikrobiyol Bul; 2020 Jul; 54(3):368-377. PubMed ID: 32755514
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of linezolid against Clostridium difficile.
Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.
Beran V; Chmelar D; Vobejdova J; Konigova A; Nemec J; Tvrdik J
Folia Microbiol (Praha); 2014 May; 59(3):209-15. PubMed ID: 24114414
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
11. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
Jiang ZD; DuPont HL; La Rocco M; Garey KW
J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207
[TBL] [Abstract][Full Text] [Related]
13. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
14. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E
Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918
[TBL] [Abstract][Full Text] [Related]
16. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion.
Fraga EG; Nicodemo AC; Sampaio JL
Braz J Infect Dis; 2016; 20(5):476-81. PubMed ID: 27542867
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
19. Metronidazole resistance in Clostridium difficile is heterogeneous.
Peláez T; Cercenado E; Alcalá L; Marín M; Martín-López A; Martínez-Alarcón J; Catalán P; Sánchez-Somolinos M; Bouza E
J Clin Microbiol; 2008 Sep; 46(9):3028-32. PubMed ID: 18650353
[TBL] [Abstract][Full Text] [Related]
20. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.
Drummond LJ; McCoubrey J; Smith DGE; Starr JM; Poxton IR
J Med Microbiol; 2003 Mar; 52(Pt 3):259-263. PubMed ID: 12621092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
